Newsroom

The European Research Council (ERC) has announced the results of the latest round of its “Proof of Concept Grant” 2024 competition. Among the researchers selected for funding is Prof. Yang Li, co-director of the Centre for Individualised Infection Medicine (CiiM) and head of the research department “Bioinformatics for Individualised Medicine”, who has thus been awarded one of the coveted ERC grants for the second time. In total, the ERC selected 134 projects for funding of 150,000 euros each. The CiiM is a branch of the Helmholtz Centre for Infection Research (HZI), which is operated jointly with the Hannover Medical School (MHH).

The long-standing President of the Thünen Institute, Prof. Dr Folkhard Isermeyer, passed away on 14 January 2025 at the age of 67. With his passing, the Thünen Institute has not only lost its ‘architect’, an excellent scientist and clever strategist, but also a personality who led with trust, an open ear and human warmth.

With viral disease emergence expected to accelerate, preparing for possible future pandemics is paramount. Beyond saving lives during outbreaks, robust pandemic preparedness safeguards economies, sustains societal functioning, and reinforces the resilience of global systems. The new EU project COMBINE (“Comparative Signature of Marburg Virus Cell Activation as a Blueprint for the Identification of Antiviral Targets against Newly Emerging Viruses”) acknowledges that understanding how viruses infiltrate host cells is crucial to combating emerging infectious diseases. The project sets out to advance our understanding of how viruses enter cells, using the Marburg Virus (MARV) as a model, and to create a blueprint for identifying new targets for antiviral strategies – a critical cornerstone of pandemic preparedness. Coordinated by the German Helmholtz Centre for Infection Research (HZI), COMBINE brings together seven partners from five European countries and will receive a total funding of 7.2 million euros over the next five years through the European Union’s “Horizon Europe” Framework Programme for Research and Innovation.

A hospital is a place where you generally don't like to go, but are glad that it's there when you need it. It's called ‘clinically clean’. But it is precisely here that we also encounter the term “hospital germ” – an ominous reminder that a place of healing can also pose a health risk. These pathogenic germs are often so resilient that only a few drugs are effective against them. Prof. Susanne Häußler, head of the department “Molecular Bacteriology” at the HZI and TWINCORE in Hannover, studies how these multi-resistant bacteria develop. In the HZI podcast InFact, she explains how faster diagnostics can also improve treatment.

A team of scientists at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg and the University of Regensburg has unveiled insights into how HIV-1, the virus responsible for AIDS, skillfully hijacks cellular machinery for its own survival. By dissecting the molecular interplay between the virus and its host, the researchers identified novel strategies that HIV-1 employs to ensure its replication while suppressing the host’s cellular defenses. The study was published in the journal Nature Structural and Molecular Biology.

Antibiotics are a double-edged sword – they should be as toxic as possible to pathogenic bacteria while being harmless to the cells of the human body. An international research team led by the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) has now developed drug candidates that achieve precisely that. The new molecules target a metabolic pathway that only occurs in bacterial cells, thus sparing human cells. The team published its results in the journal Angewandte Chemie International Edition.